Roivant Sciences (ROIV) Stock Surges 20% as Three Street Firms Initiate Coverage With Positive Ratings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Jefferies Starts Roivant Sciences (ROIV) at Buy
October 26, 2021 7:38 AM EDTJefferies analyst Dennis Ding initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $10.00.
The analyst commented, "ROIV is a diversified healthcare company employing a novel hub-and-spoke model, which enables its 10+ subsidiaries (Vants) substantial flexibility in maximizing... More
Truist Securities Starts Roivant Sciences (ROIV) at Buy
October 26, 2021 6:09 AM EDTTruist Securities analyst Robyn Karnauskas initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $15.00.
The analyst commented, "Roivants novel business model underappreciated by investors, in our view; with their evolving AI technology platform and... More
Cowen Starts Roivant Sciences (ROIV) at Outperform
October 26, 2021 5:38 AM EDTCowen analyst Yaron Werber initiates coverage on Roivant Sciences (NASDAQ: ROIV) with an Outperform rating.
The analyst commented, "Roivant aims to revolutionize drug development by integrating multiple subsidiaries discovery platforms with others manufacturing/clinical resources. Dermavants tapinarof is highly promising based on consultant... More
